or Try an Advanced Search...

    Technical Analysis for MNPR - Monopar Therapeutics Inc.

    Grade Last Price % Change Price Change
    C 0.74 1.55% 0.01
    MNPR closed up 1.55 percent on Monday, July 1, 2024, on 63 percent of normal volume. It was able to find support at its 50 day moving average.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Down
    Historical MNPR trend table...
    Date Alert Name Type % Chg
    50 DMA Support Bullish 0.00%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    50 DMA Support Bullish 1.55%
    Outside Day Range Expansion 1.55%
    Wide Bands Range Expansion 1.55%
    Down 3 Days in a Row Weakness 1.55%
    NR7 Range Contraction -0.15%
    Older End-of-Day Signals for MNPR ...

       Recent Intraday Alerts

    Alert Time
    50 DMA Support about 5 hours ago
    10 DMA Resistance about 6 hours ago
    Fell Below 50 DMA about 6 hours ago
    Down 2 % about 6 hours ago
    Down 1% about 6 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    MNPR Chart by TradingView
    Basic chart:

    Profile

    Monopar Therapeutics is a clinical stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for advanced soft tissue sarcoma; and a late-stage preclinical antibody MNPR-101.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Radiation Therapy Sarcoma Head And Neck Cancer Soft Tissue Sarcoma Mucositis Radiotherapy Oral Mucositis Otorhinolaryngology

    Is MNPR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 25 Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
    Jun 11 Monopar and NorthStar Amend & Extend Collaboration
    Jun 10 Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
    Jun 5 Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely
    Jun 3 Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
    May 24 Monopar Therapeutics CFO Tsuchimoto will retire, Radhakrishnan to succeed
    May 24 Monopar Announces CFO Succession
    May 17 Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' Now
    May 9 Monopar Therapeutics GAAP EPS of -$0.10
    May 9 Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
    See more MNPR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.73
    52 Week Low 0.2739
    Average Volume 121,797
    200-Day Moving Average 0.57
    50-Day Moving Average 0.71
    20-Day Moving Average 0.80
    10-Day Moving Average 0.76
    Average True Range 0.09
    RSI (14) 48.45
    ADX 25.81
    +DI 27.88
    -DI 20.80
    Chandelier Exit (Long, 3 ATRs) 0.82
    Chandelier Exit (Short, 3 ATRs) 0.86
    Upper Bollinger Bands 0.95
    Lower Bollinger Band 0.66
    Percent B (%b) 0.29
    BandWidth 36.76
    MACD Line 0.01
    MACD Signal Line 0.02
    MACD Histogram -0.0143
    Fundamentals Value
    Market Cap 11.02 Million
    Num Shares 14.9 Million
    EPS -0.72
    Price-to-Earnings (P/E) Ratio -1.03
    Price-to-Sales 0.00
    Price-to-Book 0.79
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.82
    Resistance 3 (R3) 0.81 0.79 0.80
    Resistance 2 (R2) 0.79 0.77 0.79 0.80
    Resistance 1 (R1) 0.76 0.76 0.75 0.77 0.80
    Pivot Point 0.74 0.74 0.73 0.74 0.74
    Support 1 (S1) 0.71 0.72 0.70 0.72 0.69
    Support 2 (S2) 0.69 0.71 0.69 0.68
    Support 3 (S3) 0.66 0.69 0.68
    Support 4 (S4) 0.67